Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients?
Background: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall s...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2016-12-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/534 |
id |
doaj-3d63a308f5b242abbdcd9c1eb2e46aeb |
---|---|
record_format |
Article |
spelling |
doaj-3d63a308f5b242abbdcd9c1eb2e46aeb2020-11-25T03:09:16ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072016-12-01111Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients?Mehrdad Payandeh0Masoud Sadeghi1Edris Sadeghi2Alireza Janbakhsh3Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, IranStudents Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, IranStudents Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, IranDepartment of Infectious Diseases and Tropical Medicine, Kermanshah University of Medical Sciences, Kermanshah, IranBackground: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections. Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months. Conclusions: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/534FISHHormone receptorsDFSTrastuzumab |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mehrdad Payandeh Masoud Sadeghi Edris Sadeghi Alireza Janbakhsh |
spellingShingle |
Mehrdad Payandeh Masoud Sadeghi Edris Sadeghi Alireza Janbakhsh Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients? International Journal of Hematology-Oncology and Stem Cell Research FISH Hormone receptors DFS Trastuzumab |
author_facet |
Mehrdad Payandeh Masoud Sadeghi Edris Sadeghi Alireza Janbakhsh |
author_sort |
Mehrdad Payandeh |
title |
Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_short |
Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_full |
Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_fullStr |
Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_full_unstemmed |
Is There any Concordance Between of IHC with FISH in HER2-Positive Breast Cancer Patients? |
title_sort |
is there any concordance between of ihc with fish in her2-positive breast cancer patients? |
publisher |
Tehran University of Medical Sciences |
series |
International Journal of Hematology-Oncology and Stem Cell Research |
issn |
2008-2207 |
publishDate |
2016-12-01 |
description |
Background: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS).
Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections.
Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months.
Conclusions: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+.
|
topic |
FISH Hormone receptors DFS Trastuzumab |
url |
https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/534 |
work_keys_str_mv |
AT mehrdadpayandeh isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients AT masoudsadeghi isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients AT edrissadeghi isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients AT alirezajanbakhsh isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients |
_version_ |
1724663689984868352 |